/PRNewswire/ Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral.
Synairgen plc(‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 2021 Scaling up and preparing for Phase III COVID-19 trial.
Synairgen plc('Synairgen' or the 'Company') Non-Executive Director Appointment Southampton, UK - 30 September 2021: Synairgen plc (LSE: SNG), the drug discovery, development and commercialisation